Professor Ali Ghoz, Trauma and Orthopaedic Surgeon at Cromwell Hospital in London, has successfully treated over 100 patients with Arthrosamid®, a new long-lasting and minimally invasive treatment to relieve pain in patients suffering with osteoarthritis (OA) of the knee.
Osteoarthritis is a long-term chronic condition that causes joints to become painful and stiff. It can occur in multiple joints, including the knee. Current treatments, such as steroid injections, can have detrimental effects on the knee joint and, even if successful, the relief provided can be short-lived. For others, total knee replacement surgery may be the only option available but with lengthy recovery times and the risk of repeat surgical procedures needed further down the line, this is often not the best choice especially for younger, active patients with significant pain and early osteoarthritis. But, despite a large suffering population, there has been very little innovation in the range of OA treatments on offer to help patients, until now.
Pioneered by hydrogel specialists, Contura International Ltd, Arthrosamid® is a long-lasting intra-articular injection, which acts a non-degradable bio-scaffold, cushions the joint, and relieves pain with a single injection1. With its safety and effectiveness profile, Arthrosamid® is a minimally invasive alternative treatment option, which may prevent or postpone the need for knee surgery. New three-year data for Arthrosamid® presented at the 2023 OARSI World Congress in Denver, Colorado, demonstrated the long-term efficacy of the injection – showing that a single injection of 6ml Arthrosamid® hydrogel maintained a statistically significant pain reduction in patients with knee OA three years after their initial treatment2.
Professor Ghoz has treated over 100 patients successfully at Cromwell Hospital, offering them this new treatment option to relieve their pain. He comments:
“I am delighted to be able to offer my patients Arthrosamid®, a minimally invasive treatment to help alleviate knee pain caused from osteoarthritis, at Cromwell Hospital. I have been very impressed and reassured by the response rates I have seen, with all patients having an initial improvement in pain (at 3 months) by 50-70%. Thank you to the team at Cromwell Hospital for supporting me in introducing this important new option for the benefit of my patients.”
Rakesh, CEO of Contura International Ltd, comments:
“Since launching the treatment two years ago, Arthrosamid® has been used to treat thousands of patients across Europe. We’ve had huge interest and many enquiries from people all over the world seeking more information and wanting potential treatment. This is not surprising given the significant discomfort knee osteoarthritis causes. Patient quality of life is terribly affected, making everyday activities really challenging. For patients unsuitable for, or simply not wanting, surgery, Arthrosamid® is a game-changing option. With over two decades of research and clinical development behind the hydrogel, the safety profile is well established and published data shows that a single injection can provide years of sustained pain relief. So, we know there is demand for a non-invasive treatment option for knee osteoarthritis in the area, and we are thrilled to be working with Professor Ali Ghoz at Cromwell Hospital and other clinical experts across Europe to ensure that patients can have access to Arthrosamid®.”
References:
1.Bliddal, H, Overgaard, A, Hartkopp, A et al. (2021) Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: A 6 Months Prospective Study. Journal of Orthopaedic Research and Therapy, 6 (2). 1188. ISSN 2575-8241.
2.Henriksen, M. et al. (2023). 3 year results from a prospective study of polyacrylamide hydrogel for knee osteoarthritis.. Osteoarthritis and Cartilage, 31(5), P682–683. doi:10.1016/j.joca.2023.02.023.